Seladelpar lysine dihydrate for the treatment of patients with primary biliary cholangitis

NICE

30 July 2025 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of seladelpar lysine dihydrate in the NHS in England.

For the time being, seladelpar lysine dihydrate should not be used for the treatment of adults with primary biliary cholangitis, including pruritus:

  • In combination with ursodeoxycholic acid if the primary biliary cholangitis has not responded well enough to ursodeoxycholic acid
  • As monotherapy if ursodeoxycholic acid cannot be tolerated

Read NICE draft guidance consultation

Michael Wonder

Posted by:

Michael Wonder